TSE.4540
Supplementary Materials
The First Quarter of the Term Ending March 31, 2023
August 3, 2022
TSUMURA & CO.
Consolidated Statements of Income | ・・・・・ | 1 |
investments, R&D expenses, etc. | ・・・・・ | 1 |
Growth rates of 129 prescription Kampo products ・・・・・ | 1 | |
Product sales | ・・・・・ | 2 |
Consolidated Balance Sheets | ・・・・・ | 3 |
Consolidated Statements of Cash Flows | ・・・・・ | 3 |
Quarterly data | ||
Consolidated Statements of Income | ・・・・・ | 4 |
Consolidated Balance Sheets | ・・・・・ | 4 |
Consolidated Statements of Cash Flows ・・・・・ | 5 | |
Product sales | ・・・・・ | 5 |
Consolidated Statements of Income | (Million yen) | ||||||||||||||
FY 3/2022 1Q | FY 3/2023 1Q | Year-on-year | Forecast for 2Q (cumulative total) | Full-year forecast for FY 3/2023 | |||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | Year-on-year | Year-on-year | Amount | % of sales | Year-on-year | Year-on-year | ||
(Amount) | (%) | (Amount) | (%) | ||||||||||||
Net sales | 31,771 | 100.0% | 34,417 | 100.0% | 2,645 | 8.3% | 68,900 | 100.0% | 5,483 | 8.6% | 138,500 | 100.0% | 8,953 | 6.9% | |
Domestic | 29,513 | 92.9% | 31,562 | 91.7% | 2,048 | 6.9% | 61,750 | 89.6% | 2,920 | 5.0% | 124,200 | 89.7% | 4,632 | 3.9% | |
Overseas | 2,257 | 7.1% | 2,855 | 8.3% | 597 | 26.5% | 7,150 | 10.4% | 2,562 | 55.9% | 14,300 | 10.3% | 4,321 | 43.3% | |
Cost of sales | 15,298 | 48.2% | 16,462 | 47.8% | 1,164 | 7.6% | 34,700 | 50.4% | 3,978 | 13.0% | 69,800 | 50.4% | 6,718 | 10.7% | |
Gross profit on sales | 16,473 | 51.8% | 17,954 | 52.2% | 1,481 | 9.0% | 34,200 | 49.6% | 1,504 | 4.6% | 68,700 | 49.6% | 2,234 | 3.4% | |
Selling, general and administrative expenses | 10,321 | 32.5% | 11,601 | 33.7% | 1,280 | 12.4% | 23,500 | 34.1% | 2,488 | 11.8% | 47,900 | 34.6% | 3,811 | 8.6% | |
Operating profit | 6,152 | 19.4% | 6,353 | 18.5% | 201 | 3.3% | 10,700 | 15.5% | (984) | (8.4)% | 20,800 | 15.0% | (1,576) | (7.0)% | |
Ordinary profit | 7,247 | 22.8% | 8,665 | 25.2% | 1,418 | 19.6% | 14,000 | 20.3% | 590 | 4.4% | 21,200 | 15.3% | (4,704) | (18.2)% | |
Profit attributable to owners of parent | 5,389 | 17.0% | 6,632 | 19.3% | 1,243 | 23.1% | 9,600 | 13.9% | (365) | (3.7)% | 15,000 | 10.8% | (3,836) | (20.4)% | |
Investments, R&D expenses, etc. | (Million yen) | ||||||||||||||
FY 3/2022 1Q | FY 3/2023 1Q | Year-on-year | Forecast for 2Q (cumulative total) | Full-year forecast for FY 3/2023 | |||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | Year-on-year | Year-on-year | Amount | % of sales | Year-on-year | Year-on-year | ||
(Amount) | (%) | (Amount) | (%) | ||||||||||||
Investments | 2,019 | 6.4% | 2,251 | 6.5% | 231 | 11.5% | 10,500 | 15.2% | 5,378 | 105.0% | 22,000 | 15.9% | 9,902 | 81.9% | |
Capital investments | 1,950 | 6.1% | 2,037 | 5.9% | 87 | 4.5% | 8,000 | 11.6% | 3,055 | 61.8% | 17,500 | 12.6% | 6,043 | 52.7% | |
R&D expenses | 1,780 | 5.6% | 2,139 | 6.2% | 358 | 20.1% | 3,700 | 5.4% | 150 | 4.2% | 7,600 | 5.5% | 286 | 3.9% | |
Advertising expenses | 108 | 0.3% | 126 | 0.4% | 18 | 16.8% | 500 | 0.7% | 231 | 86.4% | 1,000 | 0.7% | (104) | (9.5)% | |
Depreciation | 2,075 | 6.5% | 2,456 | 7.1% | 381 | 18.4% | 4,800 | 7.0% | 476 | 11.0% | 9,800 | 7.1% | 1,056 | 12.1% | |
Personnel expenses | 7,994 | 25.2% | 8,355 | 24.3% | 360 | 4.5% | 17,300 | 25.1% | 1,117 | 6.9% | 34,800 | 25.1% | 1,897 | 5.8% | |
※From the current consolidated fiscal year, the "acquisition of property, plant and equipment" has been changed to "investment amount of property, plant and equipment and software, etc." and the comparative figures have been rearranged.
Growth rates of 129 prescription Kampo products
FY 3/2016 | FY 3/2017 | FY 3/2018 | FY 3/2019 | FY 3/2020 | FY 3/2021 | FY 3/2022 | FY 3/2023 | |
1Q | ||||||||
Amount | 2.3% | 1.9% | 2.4% | 2.7% | 1.8% | 1.1% | 8.1% | 6.7% |
Number of items with higher yen sales | 68 | 95 | 63 | 83 | 66 | 82 | 110 | 101 |
1
Product sales
(Million yen) | |||||||
FY 3/2022 | FY 3/2023 | Year-on- | Year-on- | ||||
Rank | No. | Product Name | year | year | |||
1Q | 1Q | ||||||
(Amount) | (%) | ||||||
1 | ☆ | 100 | Daikenchuto | 2,430 | 2,505 | 74 | 3.1% |
2 | ☆ | 54 | Yokukansan | 1,872 | 1,933 | 60 | 3.2% |
3 | G | 41 | Hochuekkito | 1,818 | 1,881 | 63 | 3.5% |
4 | ☆ | 43 | Rikkunshito | 1,770 | 1,860 | 90 | 5.1% |
5 | G | 17 | Goreisan | 1,297 | 1,542 | 244 | 18.8% |
6 | G | 24 | Kamishoyosan | 1,205 | 1,296 | 91 | 7.6% |
7 | 68 | Shakuyakukanzoto | 1,201 | 1,281 | 79 | 6.6% | |
8 | ☆ | 107 | Goshajinkigan | 888 | 932 | 43 | 4.9% |
9 | 114 | Saireito | 847 | 864 | 17 | 2.1% | |
10 | 29 | Bakumondoto | 806 | 805 | (1) | (0.2)% | |
17 | G | 108 | Ningin'yoeito | 484 | 507 | 23 | 4.9% |
18 | G | 137 | Kamikihito | 411 | 501 | 90 | 22.0% |
23 | ☆ | 14 | Hangeshashinto | 345 | 359 | 13 | 3.9% |
Total of "Drug Fostering" Program formulations | 7,308 | 7,591 | 282 | 3.9% | |||
Total of Growing formulations | 5,217 | 5,730 | 512 | 9.8% | |||
Total of 129 prescription Kampo products | 28,377 | 30,277 | 1,900 | 6.7% | |||
☆ ："Drug Fostering" Program formulations
- ：Growing formulations
Regarding Growing prescriptions, Ninjinyoeito and Kamikihito have been added as new growth drivers from the current consolidated fiscal year, and the lineup has been changed in order to aim for write ups in treatment guidelines by building evidence.
2
Consolidated Balance Sheets | (Million yen) | ||
As of March 31 | As of June 30 | Increase / | |
2022 | 2022 | decrease | |
Total assets | 350,981 | 362,580 | 11,598 |
Current assets | 229,420 | 237,849 | 8,428 |
Liquid assets | 122,431 | 125,342 | 2,911 |
Inventories | 92,751 | 95,902 | 3,151 |
Non-current assets | 121,561 | 124,731 | 3,170 |
Property, plant and equipment | 90,040 | 91,833 | 1,793 |
Total liabilities | 92,871 | 93,512 | 640 |
Current liabilities | 45,875 | 46,799 | 923 |
Non-current liabilities | 46,996 | 46,713 | (283) |
Total net assets | 258,109 | 269,068 | 10,958 |
Consolidated Statements of Cash Flows | (Million yen) | ||
FY 3/2022 | FY 3/2023 | Year-on-year | |
1Q | 1Q | ||
Cash flows from operating activities | 3,360 | 4,785 | 1,424 |
Cash flows from investing activities | (3,101) | (4,145) | (1,044) |
Cash flows from financing activities | (2,371) | (2,418) | (47) |
Cash and cash equivalents at the end of the quarter | 59,278 | 68,022 | 8,744 |
3
This is an excerpt of the original content. To continue reading it, access the original document here.